+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autoimmune Disease Diagnostics Market - Global Forecast 2026-2032- Product Image
Autoimmune Disease Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Autoimmune Disease Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5014101
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Autoimmune Disease Diagnostics Market is projected to reach USD 6.68 Billion in 2026. It is expected to continue growing at a CAGR of 7.45%, reaching USD 10.30 Billion by 2032.

Autoimmune disease diagnostics are moving from episodic, symptom-led testing to earlier, multi-marker, and longitudinal assessment across rheumatology, gastroenterology, endocrinology, neurology, nephrology, and dermatology. Demand is supported by the high clinical burden of autoimmune disorders, delayed diagnosis in conditions such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease, and celiac disease, and the need to distinguish inflammatory, infectious, malignant, and genetic mimics.

The market is anchored by established technologies such as indirect immunofluorescence assays, ELISA, chemiluminescent immunoassays, complement testing, HLA typing, tissue transglutaminase testing, anti-cyclic citrullinated peptide testing, antinuclear antibody testing, extractable nuclear antigen panels, and disease-specific autoantibody panels. Adoption is increasingly shaped by multiplex immunoassays, laboratory automation, digital pathology, companion-style biomarker strategies, and data integration with electronic health records to improve diagnostic confidence and patient monitoring.

Transformative Shifts in the Diagnostic Landscape

The autoimmune disease diagnostics landscape is being reshaped by three structural shifts: earlier risk detection, higher-throughput laboratory platforms, and more specialized clinical decision support. Clinicians increasingly require tests that support differential diagnosis, disease activity monitoring, flare prediction, organ involvement assessment, and treatment stratification rather than single-point confirmation. This is especially relevant because many autoimmune diseases have overlapping symptoms and may require combined interpretation of serology, inflammatory markers, imaging, biopsy findings, and clinical history.

Regulatory and quality expectations are also changing. The European Union In Vitro Diagnostic Regulation has raised requirements for clinical evidence, post-market surveillance, performance documentation, and notified body review, while U.S. laboratories continue to navigate evolving oversight of laboratory-developed tests. These shifts favor manufacturers and laboratories with validated assays, traceable controls, harmonized reporting, scalable automation, and strong medical education programs that help reduce false positives, false negatives, and unnecessary downstream testing.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of autoimmune diagnostics by improving pattern recognition, workflow triage, and interpretation across complex datasets. AI-enabled image analysis can support antinuclear antibody immunofluorescence pattern classification, while machine learning models can integrate serology, inflammatory markers, genomics, medications, symptoms, imaging, pathology, and longitudinal clinical data to identify patients needing specialist referral or closer monitoring.

The cumulative impact is operational as well as clinical. AI can help laboratories reduce manual review burden, flag inconsistent results, prioritize high-risk samples, support reflex testing pathways, and strengthen quality management. Its strongest near-term value is expected in decision support and laboratory efficiency, provided models are clinically validated, bias-tested, explainable, cybersecurity-protected, and integrated into regulated diagnostic workflows with clinician oversight.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

In Asia-Pacific, autoimmune disease diagnostics benefit from expanding hospital networks, rising private diagnostics investment, and broad adoption of automated immunoassay platforms in China, India, Japan, South Korea, and Australia. Population scale, growing chronic disease awareness, medical tourism, and increasing specialist access support test utilization, although reimbursement variability, urban-rural access gaps, and uneven availability of subspecialty immunology services remain important constraints.

North America remains a high-value region because of advanced clinical laboratories, strong rheumatology and gastroenterology networks, broad use of molecular and multiplex testing, and active adoption of digital health and electronic health record integration. Europe is shaped by strong public health systems, CE-IVD requirements, clinical guideline adherence, and high standards for assay validation under the In Vitro Diagnostic Regulation. Latin America shows rising demand in Brazil and Mexico, supported by private laboratory chains, urban specialty care expansion, and growing awareness of autoimmune thyroid disease, rheumatoid arthritis, and celiac disease. The Middle East, particularly Gulf health systems, is investing in advanced hospital diagnostics, reference laboratories, and tertiary care infrastructure, while Africa’s development is tied to reference laboratory capacity, infectious disease differential diagnosis, workforce training, and improved access to specialist testing in major urban centers.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are characterized by growing private hospital groups, expanding medical tourism, and increasing use of centralized reference laboratories, especially in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. This creates demand for scalable autoimmune serology, celiac disease testing, thyroid autoantibody testing, and connective tissue disease panels. The GCC benefits from government-backed healthcare modernization, tertiary hospital investment, population screening initiatives, and demand for imported advanced diagnostic platforms that support specialist care pathways.

The European Union is a critical regulatory and commercialization benchmark because IVDR compliance affects assay classification, clinical evidence, post-market surveillance, and market access timelines. BRICS countries create large-volume opportunities, led by China, India, and Brazil, but require pricing discipline, localization, reimbursement awareness, and strong distributor or laboratory partnerships. G7 markets lead in specialty diagnostics adoption, reimbursement sophistication, digital laboratory infrastructure, and clinical research, while NATO countries collectively support resilient supply chains, laboratory interoperability, cybersecurity readiness, and healthcare security priorities relevant to uninterrupted essential diagnostic testing.

Key Country Insights Across Major Autoimmune Diagnostics Markets

The United States leads in autoimmune disease diagnostics through high test utilization, advanced reference laboratories, FDA-cleared platforms, broad insurance-linked clinical pathways, and strong adoption of multiplex panels. Canada benefits from publicly funded care, centralized provincial laboratory models, and evidence-based utilization management, while Mexico’s demand is supported by urban private diagnostics, expanding specialty clinics, and cross-border healthcare activity. Brazil is the leading Latin American opportunity due to its large population, specialty care presence, public-private laboratory networks, and rising demand for rheumatology, thyroid, and gastrointestinal autoimmune testing.

In Europe, the United Kingdom emphasizes National Health Service pathways, clinical governance, and evidence-based testing; Germany combines advanced laboratory infrastructure with strong reimbursement discipline and high automation; France, Italy, and Spain show steady demand for rheumatoid arthritis, celiac disease, autoimmune thyroid disease, systemic autoimmune rheumatic disease, and inflammatory bowel disease diagnostics; and Russia relies on major urban centers for advanced immunology testing and specialist referral. In Asia-Pacific, China and India offer scale and fast laboratory modernization supported by hospital expansion and private diagnostics growth, Japan and South Korea emphasize quality, automation, precision medicine, and standardized workflows, and Australia benefits from guideline-driven testing, robust specialist referral systems, and strong laboratory accreditation practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated assay portfolios that address high-burden conditions such as rheumatoid arthritis, lupus, celiac disease, autoimmune thyroid disease, inflammatory bowel disease, type 1 diabetes, antiphospholipid syndrome, and autoimmune liver disease. Portfolio strategy should combine established serology with multiplex, molecular, and digital interpretation capabilities that improve diagnostic specificity, support reflex testing, and reduce unnecessary repeat testing.

Companies should invest in evidence generation, health economics, laboratory workflow automation, payer-facing clinical utility data, and education for clinicians and laboratory professionals. Regional success will depend on IVDR readiness, U.S. regulatory preparedness, local reference ranges, quality-controlled distribution, reagent supply resilience, interoperability with laboratory information systems, and partnerships with hospitals, reference laboratories, academic centers, and digital health platforms.

Research Methodology

This executive summary applies a secondary research methodology using publicly available, verifiable sources, including regulatory guidance, peer-reviewed clinical literature, professional society recommendations, government health data, disease burden studies, reimbursement frameworks, laboratory accreditation standards, and public health reports. Insights are triangulated across clinical adoption, laboratory infrastructure, regulatory requirements, technology maturity, guideline relevance, and regional access patterns.

Market interpretation is based on evidence-linked indicators rather than unverified assumptions. Key inputs include diagnostic guideline relevance, assay validation requirements, automation adoption, patient access dynamics, specialist density, reimbursement environment, laboratory quality systems, and the role of reference laboratories in scaling autoimmune disease testing. No market sizing, market share, or forecasting assumptions are used in this analysis.

Conclusion

Autoimmune disease diagnostics are becoming more precise, automated, and data-integrated as healthcare systems seek earlier detection, better differential diagnosis, and improved disease monitoring. Established serology remains essential, but differentiation is shifting toward validated multiplex panels, AI-enabled interpretation, robust quality systems, standardized reporting, and evidence-based clinical utility.

Organizations that align innovation with regulatory compliance, affordability, laboratory efficiency, supply reliability, and physician confidence will be best positioned to advance clinical adoption. The strongest opportunities lie in markets where specialist access, reimbursement support, laboratory accreditation, and diagnostic infrastructure converge to support timely autoimmune disease diagnosis and long-term patient management.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Autoimmune Disease Diagnostics Market, by Product
7.1. Introduction
7.2. Assay Kits & Reagents
7.3. Instruments
7.3.1. Immunoassay Analyzers
7.3.2. Microplate Readers
8. Autoimmune Disease Diagnostics Market, by Test Type
8.1. Introduction
8.2. Autoantibodies & Immunologic Test
8.2.1. Antinuclear Antibodies
8.2.2. Cyclic Citrullinated Peptide Antibodies
8.2.3. Disease-Specific Autoantibodies
8.3. Genetic Testing
8.3.1. Chromosomal Tests
8.3.2. Molecular Tests
8.4. Imaging Tests
8.4.1. Magnetic Resonance Imaging
8.4.2. Positron Emission Tomography
8.4.3. Ultrasound
8.5. Inflammatory Markers
8.5.1. C-reactive protein
8.5.2. Erythrocyte Sedimentation Rate
9. Autoimmune Disease Diagnostics Market, by Technology
9.1. Introduction
9.2. Enzyme-Linked Immunosorbent Assay
9.3. Flow Cytometry
9.4. Immunofluorescence Assay
9.5. Multiplex Assays
9.6. Next-Generation Sequencing
9.7. Western Blotting
10. Autoimmune Disease Diagnostics Market, by Sample Type
10.1. Introduction
10.2. Blood
10.3. Saliva
10.4. Urine
11. Autoimmune Disease Diagnostics Market, by Indication
11.1. Introduction
11.2. Organ-Specific Autoimmune Disease Diagnostics
11.2.1. Graves’ Disease
11.2.2. Hashimoto’s Thyroiditis
11.2.3. Multiple Sclerosis
11.2.4. Type 1 Diabetes
11.3. Systemic Autoimmune Disease Diagnostics
11.3.1. Rheumatoid Arthritis
11.3.2. Systemic Lupus Erythematosus
11.3.3. Systemic Sclerosis
12. Autoimmune Disease Diagnostics Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Diagnostic Laboratories
12.4. Hospitals & Clinics
12.5. Research Institutions
13. Autoimmune Disease Diagnostics Market, by Distribution Channel
13.1. Introduction
13.2. Offline Sales
13.3. Online Sales
14. Autoimmune Disease Diagnostics Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Autoimmune Disease Diagnostics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Autoimmune Disease Diagnostics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Abbott Laboratories
18.2. AbbVie Inc.
18.3. AESKU.GROUP GmbH & Co. KG
18.4. Autobio Diagnostics Co., Ltd.
18.5. Beckman Coulter, Inc. by Danaher Corporation
18.6. Becton, Dickinson and Company
18.7. Bio-Rad Laboratories, Inc.
18.8. BioAgilytix Labs, LLC
18.9. bioMerieux SA
18.10. BIOSYSTEMS S.A.
18.11. Boditech Med Inc.
18.12. Chengdu Maccura Biotechnology Co., Ltd.
18.13. DiaSorin S.p.A.
18.14. Exagen Inc.
18.15. F. Hoffmann-La Roche Ltd.
18.16. FUJIREBIO by H.U. Group company
18.17. GlaxoSmithKline plc
18.18. Grifols, S.A
18.19. Hemagen Diagnostics, Inc.
18.20. JSR Life Sciences, LLC
18.21. Labcorp Holdings Inc.
18.22. Medical & Biological Laboratories Co. Ltd
18.23. Medsource Ozone Biomedicals Pvt. Ltd.
18.24. Menarini Group
18.25. Merck KGaA
18.26. Progentec Diagnostics, Inc.
18.27. PROTIA. iNC.
18.28. Quest Diagnostics, Inc.
18.29. Revvity, Inc.
18.30. RSR Limited
18.31. SD Biosensor, INC.
18.32. Sebia S.A.
18.33. Shanghai Kehua Bio-Engineering Co., Ltd.
18.34. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
18.35. Shenzhen YHLO Biotech Co.,Ltd.
18.36. Siemens Healthineers AG
18.37. Svar Life Science AB
18.38. Takeda Pharmaceutical Company Limited
18.39. Thermo Fisher Scientific Inc.
18.40. Trinity Biotech PLC
18.41. Werfen Group
List of Figures
FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MICROPLATE READERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MICROPLATE READERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MICROPLATE READERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL AUTOANTIBODIES & IMMUNOLOGIC TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL AUTOANTIBODIES & IMMUNOLOGIC TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL AUTOANTIBODIES & IMMUNOLOGIC TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ANTINUCLEAR ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ANTINUCLEAR ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTINUCLEAR ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CYCLIC CITRULLINATED PEPTIDE ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CYCLIC CITRULLINATED PEPTIDE ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CYCLIC CITRULLINATED PEPTIDE ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL DISEASE-SPECIFIC AUTOANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL DISEASE-SPECIFIC AUTOANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL DISEASE-SPECIFIC AUTOANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CHROMOSOMAL TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CHROMOSOMAL TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CHROMOSOMAL TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL IMAGING TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL IMAGING TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL IMAGING TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INFLAMMATORY MARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INFLAMMATORY MARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INFLAMMATORY MARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ERYTHROCYTE SEDIMENTATION RATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ERYTHROCYTE SEDIMENTATION RATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ERYTHROCYTE SEDIMENTATION RATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL IMMUNOFLUORESCENCE ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL IMMUNOFLUORESCENCE ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL IMMUNOFLUORESCENCE ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MULTIPLEX ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL MULTIPLEX ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL MULTIPLEX ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL WESTERN BLOTTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL WESTERN BLOTTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL WESTERN BLOTTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL GRAVES’ DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL GRAVES’ DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL GRAVES’ DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HASHIMOTO’S THYROIDITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HASHIMOTO’S THYROIDITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HASHIMOTO’S THYROIDITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL SYSTEMIC SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL SYSTEMIC SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL SYSTEMIC SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL OFFLINE SALES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL OFFLINE SALES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL OFFLINE SALES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL ONLINE SALES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ONLINE SALES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL ONLINE SALES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 183. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 184. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 185. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 186. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 187. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 188. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 189. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 190. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 191. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 192. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 193. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 194. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 195. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 213. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 214. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 215. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 216. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 217. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 218. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 219. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 220. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 221. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 222. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 223. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 224. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 225. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 227. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 228. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 230. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 231. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 232. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 233. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 234. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 235. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 236. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 237. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 238. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 239. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 240. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 241. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 244. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 245. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 246. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 247. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 248. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 249. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 250. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 251. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 252. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 253. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 254. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 255. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 256. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 273. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 274. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 275. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 276. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 277. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 278. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 279. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 280. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 281. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 282. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 283. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 284. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 285. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 286. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 289. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 290. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 291. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 292. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 293. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 294. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 295. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 296. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 297. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 298. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 299. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 300. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 301. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 304. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 305. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 306. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 307. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 308. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 309. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 310. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD MILLION)
TABLE 311. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 312. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 313. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 314. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 315. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 316. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 318. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2017-2032 (USD M

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • AESKU.GROUP GmbH & Co. KG
  • Autobio Diagnostics Co., Ltd.
  • Beckman Coulter, Inc. by Danaher Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • BIOSYSTEMS S.A.
  • Boditech Med Inc.
  • Chengdu Maccura Biotechnology Co., Ltd.
  • DiaSorin S.p.A.
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • FUJIREBIO by H.U. Group company
  • GlaxoSmithKline plc
  • Grifols, S.A
  • Hemagen Diagnostics, Inc.
  • JSR Life Sciences, LLC
  • Labcorp Holdings Inc.
  • Medical & Biological Laboratories Co. Ltd
  • Medsource Ozone Biomedicals Pvt. Ltd.
  • Menarini Group
  • Merck KGaA
  • Progentec Diagnostics, Inc.
  • PROTIA. iNC.
  • Quest Diagnostics, Inc.
  • Revvity, Inc.
  • RSR Limited
  • SD Biosensor, INC.
  • Sebia S.A.
  • Shanghai Kehua Bio-Engineering Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shenzhen YHLO Biotech Co.,Ltd.
  • Siemens Healthineers AG
  • Svar Life Science AB
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Werfen Group

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.3 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned42

Related Topics

Related Reports

Autoimmune Disease Diagnostics Market - Products, Disease Types and Test Types - Product Image

Autoimmune Disease Diagnostics Market - Products, Disease Types and Test Types

  • Report
  • 338 Pages
  • Global
From
Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report by Type, Product, Test, End Use, Region, and Segment Forecasts, 2026-2033 - Product Image

Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report by Type, Product, Test, End Use, Region, and Segment Forecasts, 2026-2033

  • Report
  • 129 Pages
  • Global
From
Autoimmune Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Autoimmune Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Autoimmune Disease Diagnostics Market Report by Type, Indication, End-User, Countries and Company Analysis 2026-2034 - Product Image

Autoimmune Disease Diagnostics Market Report by Type, Indication, End-User, Countries and Company Analysis 2026-2034

  • Report
  • 200 Pages
  • Global
From
Autoimmune Disease Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Autoimmune Disease Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.